Merrill raises price target on Repros on Androxal hopes


Repros Therapeutics (RPRX) gets another vote of confidence (see Brean's commentary) from the sell-side, as BofA/ML raises the price target on the shares to $35 from $25.

The rationale: A derisked outlook for Androxal.

Shares +1.7% premarket

See previous Androxal coverage here

From other sites
Comments (1)
  • karlis44
    , contributor
    Comments (63) | Send Message
     
    If the data remains solid for Androxal. Which likely it will. It possibly could become a takeover by its testosterone (T) competitors. Since there are so many young and older men who wish to preserve gonadal function be it sperm or otherwise. To do what Androxal does you would need to use T + human chorionic gonadotropin,( hCG by injection), for fertility, better sexual function and avoid tetsicular and even penile atrophy. You could even make an argument that Androxal is a quasi-orphan drug. Having used Clomophine Citrate ( CC) for many years in several hundred men there are no significant safety isssues that I have seen or in studies 3 years long. "Funky" mood is the bigget problem mostly seen in the younger men using CC and is the reason they stop. In the Androxal data the drop out rate is low. The "cis" isomer of CC which likely produces the "estrogenic" mood dysfunction has been removed. Could this be a take-over situation? 
    Karlis Ullis, MD
    kullismd@gmail.com
    drkarlisullis.com
    18 Sep 2013, 12:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs